Clinical Trials

258 enrolled 16 charts

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Radiation Injuries, Salivary Gland Neoplasms, Xerostomia

NCT07332247 2026-02-04

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

94 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Neoplasms

NCT05807880 2026-01-23

ALTER-HN005

59 enrolled

Nasopharyngeal Neoplasms

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

60 enrolled

Phase NA Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT02253238 2025-11-06

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

427 enrolled

Phase 2 Active not recruiting

Dehydration, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

NCT04925544 2025-10-21

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

13 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05305131 2025-09-23

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

50 enrolled

Phase 2 Enrolling by invitation

Nasopharyngeal Neoplasms

NCT06688175 2025-08-07

IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

32 enrolled

Nasopharyngeal Neoplasms

NCT05581550 2025-07-20

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

15 enrolled

Nasopharyngeal Neoplasms

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT07042711 2025-06-29

Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients

300 enrolled

Nasopharyngeal Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04875611 2025-04-24

NIVONASO-21

32 enrolled

Nasopharyngeal Neoplasms

NCT06682442 2025-04-20

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Phase NA Recruiting

66 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05587374 2025-01-23

GEMSTONE

490 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06349889 2025-01-15

Adebrelimab and Chemoradiotherapy in High-risk LANPC

50 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT06414577 2024-12-30

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

38 enrolled

Nasopharyngeal Neoplasms

NCT06733948 2024-12-13

ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients

50 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Phase 1/2 Completed

50 enrolled 13 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

NCT03813394 2024-11-22

2018/00947

48 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT06611826 2024-09-25

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

41 enrolled

Nasopharyngeal Neoplasms

NCT02875613 2024-08-28

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

Phase 2 Terminated

6 enrolled 8 charts

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04995185 2024-05-16

18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study

9 enrolled

Nasopharyngeal Carcinoma, Hypoxia, Nasopharyngeal Neoplasms

NCT06019130 2024-05-16

NPC-Nivo

57 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06268600 2024-04-11

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

Phase NA Recruiting

320 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Hypothyroidism, Nasopharyngeal Neoplasms

NCT03427827 2024-04-09

DIPPER

450 enrolled

Nasopharyngeal Neoplasms

NCT03791944 2024-02-23

3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Neoplasms

NCT05564286 2024-02-06

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Phase 3 Completed

116 enrolled

GynecologicHead & Neck

Uterine Cervical Neoplasms, Nasopharyngeal Neoplasms, Vomiting

NCT05385926 2024-02-05

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

34 enrolled

Nasopharyngeal Neoplasms

NCT05198479 2023-10-11

SG-AAA-II-01

25 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04850235 2023-06-22

Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Phase 1 Unknown

36 enrolled

Nasopharyngeal Neoplasms

NCT03180476 2023-04-14

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

21 enrolled

Phase 2 Not yet recruiting

Nasopharyngeal Neoplasms

NCT04870905 2023-03-06

Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Neoplasms

NCT00941538 2023-02-28

CRCSTNPC

Phase NA Unknown

87,600 enrolled

Nasopharyngeal Neoplasms

NCT05628922 2022-11-29

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

198 enrolled

Nasopharyngeal Neoplasms

NCT03837808 2022-11-07

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Phase 3 Unknown

384 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT02292368 2022-09-01

Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia

30 enrolled

Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Xerostomia

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

48 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03854838 2022-04-29

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

25 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT00370890 2022-02-17

A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy

Phase 3 Completed

104 enrolled

Nasopharyngeal Neoplasms

NCT02874651 2022-01-11

ADVANCE

Phase 2 Terminated

25 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05101889 2021-11-01

Benefits of Immunonutrition in Patients With Head and Neck Cancer Receiving Chemoradiation

110 enrolled

Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Stomatitis

NCT03096808 2021-10-26

Adaptive Radiotherapy for Head and Neck Cancer

64 enrolled

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms

NCT01528618 2021-10-04

Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Phase 3 Completed

362 enrolled

Nasopharyngeal Neoplasms

NCT03942380 2021-09-21

Cell-free Tumor DNA in Head and Neck Cancer Patients

Phase NA Unknown

500 enrolled